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Background: A lot of empirical studies have been conducted to evaluate the prevalence of depression and anxiety
among Chinese adults with cancer. We aimed to conduct a meta-analysis in order to evaluate the prevalence and
odds ratios of depression and anxiety in Chinese adults with cancer compared with those without.
Methods: The three most comprehensive computerized Chinese academic databases-CNKI, Wangfang and Vip
databases-were systematically screened through September 2012. PubMed and Web of Science (SCIE) were also
searched from their inception until September 2012 without language restrictions, and an internet search was also
used. Case–control studies assessing the prevalence of depression and anxiety among Chinese adults with cancer
were analyzed. Study selection and appraisal were conducted independently by three authors. The non-weighted
prevalence, pooled random-effects estimates of odds ratio (OR) and 95% confidence intervals (CI) were all
calculated.
Results: Seventeen eligible studies with a total of 3497 subjects were included. The prevalence of depression and
anxiety were significantly higher in adults with cancer compared with those without (Depression: 54.90% vs.
17.50%, OR = 7.85, 95% CI = 5.56-11.07, P = 0.000; Anxiety: 49.69% vs. 18.37%, OR = 6.46, 95% CI = 4.36-9.55, P = 0.000),
the same situation was also observed in subgroup of control groups, assessment methods and cancer types.
Although no difference of depression was observed in studies utilizing clinical diagnosis compared with self-report,
the OR of anxiety in adults with cancer compared with those without was higher in studies utilizing clinical
diagnosis (OR = 8.42, 95% CI = 4.83-14.70) than self-reports (OR = 5.83, 95% CI = 3.64-9.34). The ORs of depression
and anxiety in cancer patients compared with disease group (Depression: OR = 6.03, 95% CI = 4.23-8.61; Anxiety:
OR = 4.40, 95% CI = 3.05-6.36) were lower than in those compared with normal group (Depression: OR = 13.58,
95% CI = 6.26-29.46; Anxiety: OR = 15.47, 95% CI = 10.00-23.95).
Conclusions: We identified high prevalence rates of depression and anxiety among Chinese adults with cancer.
The findings support that the prevalence of depression and anxiety among adults with cancer should receive more
attention in Chinese medical settings.Background
Depression and anxiety are psychological and physio-
logical states characterized by a collection of physical,
emotional, and behavioral components [1,2]. They are
common psychological disorders that can impair health-
related quality of life (including physical, emotional and* Correspondence: liewang@mail.cmu.edu.cn
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reproduction in any medium, provided the orsocial dysfunction), significantly increase mortality rate
and lead to a massive medical costs [3-6].
Cancer is considered as a serious and potentially life-
threatening illness, and even as deadly diseases without
treatment (such as some advanced cancers), which has an
effect on psychological and physiological states of patients.
Unsurprisingly, various studies have demonstrated the
high levels of depression and anxiety in cancer patients
using a variety of assessment methods. Based on foreign
reviews, which mainly included the studies from devel-
oped countries like America and UK, the prevalence ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients were 0%-38% and 4.5%-58% respectively
[7-10]. The prevalence of anxiety varied from 0.9% to
49% in one review of 58 studies [10], and the range was
narrower (5.1%-23%) in large studies using standard-
ized psychiatric interviews [7,11]. In China, the preva-
lence of depression and anxiety in cancer patients were
25.8%-58% and 32%-40% respectively [12-14].
Cancer patients might be vulnerable to depression and
anxiety for many reasons: reactions to cancer diagnosis,
the presence of unpleasant symptoms associated with
cancer (such as pain, nausea and fatigue), and concerns
about disease recurrence or progression. Besides, the
physiologic effects of certain treatments (such as high-dose
interferon therapy, radiotherapy and chemotherapy) also
influenced anxiety and depression [15,16]. Cancer patients
with depression may present with worthlessness, hopeless-
ness, lose of energy and interest and suicidal preoccupation
[17,18]. And many cancer patients are also anxious, because
anxiety is a response to a threat like cancer [19,20], and
anxiety has been shown to frequently coexist with depres-
sion [17,21]. Sometimes anxiety and depression after cancer
diagnosis are adaptive, and may not present a problem.
However, some patients continue to have high levels of
depression and anxiety that persist for weeks or months,
and the untreated anxiety and depression can lead to
difficulty with symptom control, hampered treatment
decision-making, poor compliance with treatment,
prolonged recovery times and impaired quality of life
[9,18,22,23].
Nevertheless, evidence is accumulating to suggest that
identification and treatment of depression and anxiety
among cancer patients will result in reduction in disease
progression, improvement in survival rates, reduction in
medical costs and improvement in quality of life [22,24,25].
Two recent meta-analyses suggested that compared
with control group, psychological intervention effectively
improved physical and mental condition of Chinese cancer
patients [26,27]. Likewise, some systematic reviews
suggested that psychological interventions, like cognitive
behavioral therapy (CBT), could be effective against anxiety
and depression in cancer patients and have good potential
for dissemination in routine clinical practice in America
[28,29]. Psychosocial interventions to treat depression and
anxiety were also effective even in patients with advanced
cancer [29,30].
It should be noted that before antidepressant/anxiolytic
medication, and psychotherapy are performed for cancer
patients with psychological disorders, the initial recommen-
dation is for evaluation, diagnostic studies, and correction
of factors potentially contributing to psychological disor-
ders [29]. Subsequently, effective interventions and special
optimum care could be developed for cancer patients based
on these findings. Consequently, the first thing we will do isto evaluate the overall prevalence of depression and anxiety
in Chinese adults with cancer before planning treatment
provision. Although there are many studies evaluating the
level of depression and anxiety in Chinese cancer patients,
there are some gaps in literatures. First, some studies did
not use a control group. We cannot know the level of
depression and anxiety of cancer patients compared with
other populations. Second, sample size of individual study
assessing psychological distress in cancer patients is usually
small. Last, a recent Chinese study used the data from 36
cancer registry sites in China and from Third Chinese
Death Cause Survey (accepted by GLOBOCAN 2008)
to estimate the incidence and mortality rates of cancers
in 2008. The numbers of new cases and deaths from cancer
was 2.82 million (22.3% of world total) and 1.96 million
(25.9%) in China in 2008, and the number will forecast to
hit 2.99 million and 2.07 million by 2010, 3.88 million and
2.76 million by 2020, and 4.87 million and 3.60 million by
2030 [31]. Now there has not been a quantitative review,
namely meta-analysis, to assess the prevalence of depres-
sion and anxiety in Chinese adults with cancer compared
with those without, and this situation is similar to foreign
countries. Many foreign reviews of cancer patients with
psychological distress were only the qualitative literature re-
views [9,32,33] or the included studies of the meta-analysis
did not use control group as comparison [7].
Therefore, the present meta-analysis aims to synthesize
individual study evaluating depression and anxiety in
Chinese adults with cancer, and to assess the prevalence
and odds ratio (OR) of depression and anxiety in Chinese
adults with cancer compared with those without.
Methods
Literature search
A systematic search was conducted to identify published
literature on the prevalence of depression and anxiety in
Chinese adults with cancer. The CNKI database (China
National Knowledge Infrastructure), Wanfang database,
and Vip database, which are the three most comprehen-
sive Chinese academic database, were searched from their
inception until September 2012. We used ‘depression or
depressive disorders or depressive symptoms’ and ‘anxiety
or anxiety disorder or anxiety symptoms’ combined with
‘cancer or oncology or malignant neoplasm or malignant
tumour’ as search themes in the article titles, abstracts
and keywords. The reference lists of relevant articles
obtained were also screened.
In order to expand searches, PubMed and Web of
Science (SCIE) were searched from their inception
until September 2012 without language restrictions, and
an internet search was also used (e.g., www.google.com).
The search strategy was: (neoplasms[MeSH Terms] OR
cancer[Title/Abstract] OR neoplasms[Title/Abstract] OR
oncology[Title/Abstract]) AND (China[MeSH] OR China
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(depression [MeSH] OR depressive disorder [MeSH]
OR depression[Title/Abstract] OR depressive disorder
[Title/Abstract] OR depressive symptoms[Title/Abstract]
OR anxiety[MeSH] OR anxiety disorders[MeSH] OR anx-
iety[Title/Abstract] OR anxiety disorders[Title/Abstract]
OR anxiety symptoms[Title/Abstract]).
The screening of the abstracts/titles and full-text articles
were performed twice by three authors (YLY, LL and YW)
independently to reduce reviewer bias and errors.
Inclusion and exclusion criteria
We included all studies in which: (1) the subjects were
aged 18 or older; (2) the subjects of cancer group were
patients diagnosed with cancer; (3) case–control studies
were eligible, including cancer group and non-cancer
control group; (4) studies were included to those involving
more than 30 adults with cancer; (5) the subjects had a
depression and anxiety according to clinical diagnosis as
described in DSM-IV (Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition) [34] or CCMD
(Chinese Classification of Mental Disorders) [35] or
HRSD/HRSA (Hamilton Rating Scale for Depression
and Hamilton Rating Scale for Anxiety) [36,37], or the
depression and anxiety of both cancer group and control
group were identified by self-report questionnaires that
previous studies have established the reliability of them as
a measure of depression and anxiety at home and abroad;
(6) the prevalence of depression and anxiety were both
reported in cancer group and control group; (7) the sub-
jects were from Mainland China (Hong Kong and Macao
were excluded due to the long-term European influence).
We excluded studies in which: (1) the studies only included
cancer patients; (2) it was not sure if the control group
excluded the cancer patients; (3) depression and anx-
iety were measured with the self-edited scales in China
that are not widely used and accepted at home and
abroad. Eligibility judgment and data extraction were
recorded and carried out independently by two authors
(LL and YW) in a standardized manner. Any disagree-
ments with them were resolved by discussion and the
involvement of another author (LW).
Quality assessment
Although the existing checklists and quality assessment
scales in observational studies is controversial [38], the
Newcastle-Ottawa Scale for assessing quality of observa-
tional and nonrandomized studies was adapted for use
[39]. The instrument evaluated observational studies
based on three criteria: selection of cases, comparability
of study groups and assessment of outcome or exposure.
We defined three categories: the study was considered to
have high quality (low risk of bias) if it scored seven points
or above, studies that scored 1 or zero for selection or zerofor comparability or for assessment of outcome or exposure
were categorized as having low quality (high risk of bias),
studies that scored in between were considered as having
medium quality (moderate risk of bias). Any disagreements
with raters (LL and YW) were resolved by discussion and
the involvement of another author (LW).
Meta-analysis
Assessment of overall effect size
The effect size of OR is defined as the ratio of odds
(odds = Probability/(1-probability) of depression and anx-
iety occurring in cancer group compared with non-cancer
group. An OR greater than 1 indicates that depression/
anxiety is more likely to occur in cancer group compared
with control group, while an OR less than 1 indicates that
the depression/anxiety is less likely to occur in cancer
group. The pooled random-effects estimates of OR and
95% confidence intervals (CI) were calculated by standard
methods using the inverse variance weighting method,
ensuring that the larger more precise estimates were given
relatively more weighting, and non-weighted prevalence
rates were also calculated. A random effects model was
used because it involves the assumption of statistical het-
erogeneity between studies [40,41]. For zero cell counts,
the standard method of adding 0.5 to each cell count was
used [42]. Overall effects were analyzed using the statis-
tical software Stata v11.0.
Assessment of heterogeneity
Heterogeneity was evaluated with the Q statistic and I2
statistic. The Q statistic is used to assess whether dif-
ferences in results are compatible with chance alone. If
the p value of Q statistic is above 0.05, it indicates that
there is no significant heterogeneity [43], but the Q
statistic is sensitive to the number of studies [44]. To
complement the Q statistics, the I2 statistic which denotes
the variance among studies as a proportion of the total
variance was also calculated and reported, because I2 is
not sensitive to the number of studies [44]. Larger values
of I2 show increasing heterogeneity. An I2 of 0% shows no
observed heterogeneity, while 25% shows low, 50% moder-
ate, and 75% high levels of heterogeneity [45].
Subgroup analyses
When the hypothesis of homogeneity was rejected by the
Q statistic and I2 statistic, subgroup analysis was conducted
in order to explore potential moderating factors for hetero-
geneity [44]. Meanwhile, some studies in our meta-analysis
included multiple groups (e.g. liver cancer patients and
breast cancer patients were compared with a single control
group). Subgroup analysis was also used to make sure
that each patient was included only once in different
subgroups. In our study, subgroup analyses were conducted
for moderating factors, including control groups’ type
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of depression/anxiety (clinical diagnosis vs. self-report
questionnaire) and cancer types. However, due to a few of
studies (the number is less than or equal to 3) separately
reporting the OR for depression and anxiety in patients
with breast cancer, lung cancer, liver cancer, the subgroup
comparison of depression and anxiety in different types of
cancer patients were not analyzed.
Assessment of publication bias
The potential of publication bias of the included studies
was first examined by funnel plot symmetry. A funnel
plot is a useful graph designed to check the existence of
publication bias in meta-analyses. A symmetric funnel
shape indicates that publication bias is unlikely, but an
asymmetric funnel suggests the possibility of publication
bias [46]. However, some authors have argued that visual
interpretation of funnel plots is too subjective to be usefulRecords identified through 
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non-cancer control group (n = 38). Other reasons in-
cluded the simple size, the age of subjects, methods of
depression and anxiety assessment, and the composition
of control group.
In order to expand searches, we also searched the
international databases of PubMed, SCIE (as shown in
Figure 2), and an internet search (e.g., www.google.com).
However, we did not find any literatures that met our in-
clusion and exclusion criteria through the international
databases search.
Characteristics of included studies
Due to the different types of control groups, the 17 studies
with a total of 3497 subjects produced four subgroups: (1)
depression in cancer vs. disease control group (N = 14); (2)
depression in cancer vs. normal control group (N = 8);
(3) anxiety in cancer vs. disease control group (N = 12);
(4) anxiety in cancer vs. normal control group (N = 6)
(Figure 1). Study characteristics were listed in Table 1.
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Figure 2 Selection process of studies for the review (international daarticles and 2 master’s theses, were published from
2001 to 2010, except for one in 1989. Of the 17 studies
three were conducted among breast cancer patients,
three among liver cancer patients (one study included
both breast cancer and liver cancer patients), two among
lung cancer patients, one among esophageal cancer, one
among nasopharynx and liver cancer patients, and other
studies among different types of cancers. In all of these
studies, in addition to one study of primary liver cancer
diagnosed by specialist physician [58], different types of
cancer were confirmed by the physicians on the basis of
cytologic and pathological diagnosis. Regarding to the
disease control group, chronic hepatitis [56,58], diabetes
[63], tuberculosis [51], benign tumor [62], and other
non-cancer medical patients [50,52,54,55,57,60,61,65]
were included. Finally, the levels of depression and anx-
iety were assessed by clinical diagnosis method in five
studies [50,52,53,64,66], while that of the other twelve
studies was assessed by self-report questionnaires like
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Table 1 Characteristics of the included studies
Author & Years Depression/
Anxiety
Participants Mean age Age range Depression/Anxiety Mean score Type of cancer Type of control Prevalence of
depression/
anxiety (%)
(cancer, n) assessment method
and cut-off(control, n)
Yang & Bao, 2003 Depression 96 53.67 22–76 self-report 47.96 ± 6.73 Mixed Disease control 63.5
96 – – (SDS index ≥0.5) 32.32 ± 5.86 17.7
Anxiety 96 53.67 22–76 self-report 49.23 ± 7.68 Mixed Disease control 60.4
96 – – (SAS index ≥0.5) 34.06 ± 5.01 13.5
Tang, 2008 Depression 150 67 60–82 self-report – Mixed Disease control 48
50 – – (SDS total score ≥11) – 16
Long et al., 2008 Depression 46 51 36–63 self-report – Mixed Disease control 63.04
50 50 30–59 (SCL-90-D mean≥ 1.5) – 6
Anxiety 46 51 36–63 self-report – Mixed Disease control 89.13
50 50 30–59 (SCL-90-A mean≥ 1.39) – 62
Zhang et al., 2008 Depression 60 55.9 >18 self-report 52.70 ± 8.70 Mixed Disease control 73.3
60 54.8 >18 (SDS standard score≥ 50) 43.98 ± 9.35 31.7
Depression 60 55.9 >18 self-report 52.70 ± 8.70 Mixed Normal control 73.3
60 54.8 >18 (SDS standard score≥ 50) 38.43 ± 7.59 8.3
Anxiety 60 55.9 >18 self-report 52.95 ± 8.35 Mixed Disease control 70
60 54.8 >18 (SAS standard score ≥ 50) 45.82 ± 10.01 48.3
Anxiety 60 55.9 >18 self-report 52.95 ± 8.35 Mixed Normal control 70
60 54.8 >18 (SAS standard score ≥ 50) 35.92 ± 8.04 11.7
Tao et al., 2005 Depression 72 47 21–69 self-report 0.54 ± 0.05 Nasopharynx/
liver cancer
Disease control 77.8
30 43 22–65 (SDS index≥ 0.51) 0.42 ± 0.06 23.3
Depression 72 47 21–69 self-report 0.54 ± 0.05 Nasopharynx/
liver cancer
Normal control 77.8
30 42 23–65 (SDS index≥ 0.51) 0.39 ± 0.05 10
Anxiety 72 47 21–69 self-report 50 ± 8 Nasopharynx/
liver cancer
Disease control 83.3
30 43 22–65 (SAS standard score ≥ 41) 37 ± 5 40
Anxiety 72 47 21–69 self-report 50 ± 8 Nasopharynx/
liver cancer
Normal control 83.3
30 42 23–65 (SAS standard score ≥ 41) 32 ± 5 13.3
Liu et al., 2001 Depression 45 59.24 24–78 clinical diagnosis 16.78 ± 7.75 Mixed Normal control 55.56

















Table 1 Characteristics of the included studies (Continued)
Anxiety 45 59.24 24–78 clinical diagnosis 14.82 ± 6.51 Mixed Normal control 46.67
45 – – (HRSA total score ≥ 14) 6.47 ± 4.73 6.67
Zhang et al., 2009 Depression 100 58.86 35–76 clinical diagnosis 42.46 ± 12.74 Breast cancer Normal control 89
100 – – (HRSD total score≥ 20) 34.97 ± 8.31 18
Anxiety 100 58.86 35–76 clinical diagnosis 43.24 ± 10.38 Breast cancer Normal control 78
100 – – (HRSA total score ≥ 14) 32.25 ± 8.26 22
Wang et al., 2005 Depression 60 58 34–75 self–report – Lung cancer Normal control 39.58
30 51 26–68 (SDS standard score≥ 50) – 10
Anxiety 60 58 34–75 self-report – Lung cancer Normal control 43.75
30 51 26–68 (SAS standard score ≥ 50) – 6.67
Tian et al., 2005 Depression 112 55.3 36–72 self-report 52.21 ± 5.61 Liver cancer Disease control 53.6
152 45.6 30–60 (SDS standard score≥ 50) 44.45 ± 7.66 16.4
Anxiety 112 55.3 36–72 self-report 51.1 ± 4.64 Liver cancer Disease control 51.8
152 45.6 30–60 (SAS standard score ≥ 50) 42.99 ± 7.17 24.3
Liu, 2006 Depression 124 48 18–70 clinical diagnosis 16.95 ± 0.70 Mixed Disease control 33.26
60 – 18–70 (HRSD total score≥ 20) 6.80 ± 1.14 3.33
Anxiety 124 48 18–70 clinical diagnosis 9.39 ± 0.51 Mixed Disease control 29.84
60 – 18–70 (HRSA total score ≥ 17) 6.30 ± 0.83 6.67
Depression 124 48 18–70 clinical diagnosis 16.95 ± 0.70 Mixed Normal control 33.26
60 – 18–70 (HRSD total score≥ 20) 4.67 ± 0.92 1.67
Anxiety 124 48 18–70 clinical diagnosis 9.39 ± 0.51 Mixed Normal control 29.84
60 – 18–70 (HRSA total score ≥ 17) 3.63 ± 0.67 1.67
Yuan & Zheng, 2004 Depression 30 36.1 34–38 self-report 41.83 ± 12.83 Breast cancer Disease control 23.3
30 35.3 25–47 (SDS standard score > 53) 35.63 ± 6.99 0
Anxiety 30 36.1 34–38 self–report 48.93 ± 13.35 Breast cancer Disease control 33.3
30 35.3 25–47 (SAS standard score > 50) 39.30 ± 9.01 3.3
Gao et al., 1989 Depression 245 46.1 20–76 self-report – Mixed Disease control 73.1
232 46.4 20–74 (CES-D total score≥ 16) 10.96 ± 6.46 22.5
Anxiety 245 46.1 20–76 self-report – Mixed Disease control 31.1
232 46.4 20–74 (STAI total score≥ 27) 13.92 ± 8.15 4.8
Chen & Gao, 2010 Depression 90 53.5 38–79 clinical diagnosis – Esophageal cancer Disease control 46.7
86 51.8 36–80 (HRSD total score≥ 20) – 12.8

















Table 1 Characteristics of the included studies (Continued)
86 51.8 36–80 (HRSA total score≥ 7) – 17.4
She, 2009 Depression 142 44.53 15–82 self-report 50.85 ± 11.57 Mixed Disease control 60.6
149 44.53 15–82 (SDS standard score≥ 50) 46.09 ± 12.16 38.3
Anxiety 142 44.53 15–82 self-report 47.80 ± 10.8 Mixed Disease control 47.2
149 44.53 15–82 (SAS standard score ≥ 50) 44.51 ± 10.04 23.5
Zhao et al., 2001 Depression 65 51.5 29–71 self-report 0.54 ± 0.08 Liver cancer Disease control 43.08
65 – – (SDS index ≥0.5) 0.27 ± 0.12 9.23
Anxiety 65 51.5 29–71 self-report 36.86 ± 6.47 Liver cancer Disease control 24.62
65 – – (SAS standard score ≥ 50) 27.1 ± 9.76 13.69
Depression 65 51.5 29–71 self-report 0.41 ± 0.09 Breast cancer Disease control 20
65 – – (SDS index ≥0.5) 0.27 ± 0.12 9.23
Anxiety 65 51.5 29–71 self-report 44 ± 8.36 Breast cancer Disease control 20
65 – – (SAS standard score ≥ 50) 27.1 ± 9.76 13.96
Wan et al., 2004 Depression 100 44.51 20–70 self-report 15.06 ± 11.5 Primary liver cancer Disease control 49
100 – – (CES-D total score≥ 16) 11.03 ± 15.06 27
Depression 100 44.51 20–70 self-report 15.06 ± 11.5 Primary liver cancer Normal control 49
100 – – (CES-D total score≥ 16) 8.08 ± 8.44 17
Zhang et al., 2003 Depression 155 – >18 Clinical diagnosis 21 ± 9 Lung cancer Normal control 43.2
155 – >18 (HRSD total score >8) 9 ± 4 16.1
Abbreviations: SDS self-rating depression scale, SAS self-rating anxiety scale, SCL-90-D symptom checklist 90-depression, SCL-90-A, symptom checklist 90-anxiety, HRSD hamilton rating scale for depression, HRSA
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Ratings of study quality for each of the Newcastle-
Ottawa criteria were presented in Table 2. As shown in
Table 2, higher scores reflect the better study quality,
and the average scores of all studies were above 5. Seven
studies were judged to have low quality for selection of
cases or assessment of outcome or exposure and two of
high quality; other studies were rated as medium quality.
Prevalence rates of depression and anxiety in cancer patients
As shown in Table 3, the overall prevalence of depression
and anxiety was higher in adults with cancer compared
with those without (P < 0.001). This finding was consistent
when the prevalence was determined by control groups,
method of depression/anxiety assessment and cancer types
(P < 0.001).
The overall prevalence of depression and anxiety were
54.6% and 49.69% in Chinese adults with cancer, and the
prevalence of depression and anxiety were 18.37% and
17.50% in non-cancer group. This prevalence of depression
was higher in studies utilizing self-reports than in studies
using clinical diagnosis among cancer patients (58.11% vs.
47.49%, P = 0.000), and the same situation was also ob-
served among control group (19.65% vs. 11.90%, P = 0.000).
Meanwhile, the prevalence of anxiety was also higher
in self-reports than in clinical diagnosis among cancer
patients (51.74% vs. 44.93%, P = 0.012), and the sameTable 2 Assessment of study quality
Studies Quality Indi
1 2 3 4
Yang & Bao, 2003 Yes No No Yes
Tang, 2008 Yes No No Yes
Long et al., 2008 Yes No No Yes
Zhang et al., 2008 Yes No Yes Yes
Tao et al., 2005 Yes No Yes Yes
Liu et al., 2001 Yes No Yes Yes
Zhang et al., 2009 Yes No Yes Yes
Wang et al., 2005 Yes No Yes Yes
Tian et al., 2005 Yes No No Yes
Liu, 2006 Yes No Yes Yes
Yuan & Zheng, 2004 Yes No No Yes
Gao et al., 1989 Yes No No Yes
Chen & Gao, 2010 Yes No No Yes
She, 2009 Yes No No Yes
Zhao et al., 2001 Yes No No Yes
Wan et al., 2004 Yes No Yes Yes
Zhang et al., 2003 Yes No Yes Yes
Abbreviations: 1 indicates cases independently validated; 2, cases are representative
5A, study controls for age/gender; 5B, study controls for additional factor(s); 6, asce
record; 7, same method of ascertainment used for cases and controls; and 8, nonresituation was observed among control group (20.27%
vs. 12.82%, P = 0.002).
Odds ratios of depression and anxiety in cancer patients
A pooled random effects meta-analysis was conducted
using data from 17 studies, which estimated the levels of
depression and anxiety in adults with cancer compared
with those without. This analysis included data for 1,711
adults with cancer and 1,740 without cancer. As shown
in Figures 3 and 4, the odds of depression was associated
with a 7.85-fold increased risk of cancer patients when
compared with control group (OR = 7.85, 95% CI = 5.58-
11.07; p = 0.000), and the odds of anxiety was also more
than six times as high in cancer patients compared with
control group (OR = 6.46, 95% CI = 4.36-9.55; p = 0.000).
However, the heterogeneity analysis of the effect sizes
of depression (Q = 78.36, p = 0.000; I2 = 73.2%) and
anxiety (Q = 61.21, p = 0.000; I2 = 72.2%) showed that
there was a relatively high amount of heterogeneity in
our meta-analysis.
Subgroup analyses
As shown in Table 4, the ORs of depression and anxiety
were significantly increased in adults with cancer compared
with those without on moderating factors, including the
subgroup of control groups, assessment methods of depres-
sion/anxiety and cancer types. The ORs of depression andcators from Newcastle-Ottawa scale
5A 5B 6 7 8 Total score
Yes Yes No Yes No 5
Yes Yes No Yes No 5
Yes Yes No Yes No 5
Yes Yes No Yes No 6
Yes Yes No Yes No 6
Yes Yes Yes Yes No 7
Yes Yes No Yes No 6
Yes Yes No Yes No 6
Yes Yes No Yes No 5
Yes Yes Yes Yes No 7
Yes Yes No Yes No 5
Yes Yes No Yes No 5
Yes Yes No Yes No 5
Yes Yes No Yes Yes 6
Yes Yes No Yes Yes 6
Yes Yes No Yes No 6
Yes Yes Yes Yes No 7
of population; 3, community controls; 4, controls have no history of cancer;
rtainment of depression/anxiety by blinded structured interview or secure
sponse rate the same for cases and controls.
Table 3 Unadjusted prevalence of depression and anxiety in adults with and without cancer
No. of studies No. of subjects Cancer subjects (%) Non-cancer subjects (%)
Depression (All) 17 3484 54.90*** 17.50
Control group
Disease control 13 2554 54.84*** 19.61
Normal control 8 1286 55.03*** 12.98
Method of depression assessment
Clinical diagnosis 5 1010 47.49*** 11.90
Self-report questionnaire 12 2474 58.11*** 19.65
Cancer type
Breast cancer 3 380 55.90*** 12.97
Lung cancer 2 400 42.33*** 15.14
Liver cancer 3 794 49.34*** 17.99
Anxiety (All) 14 2684 49.69*** 18.37
Control group
Disease control 11 2154 46.64*** 20.30
Normal control 6 786 57.27*** 12.00
Method of depression assessment
Clinical diagnosis 4 650 44.93*** 12.82
Self-report questionnaire 10 1974 51.74*** 20.27
Cancer type
Breast cancer 3 390 58.46*** 16.41
Lung cancer 1 90 43.33*** 6.67
Liver cancer 2 394 41.81*** 21.20
*** Prevalence of depression and anxiety significantly greater in patients with cancer compared with a non-cancer control group (P < 0.001).
Note: The No. of studies per row is based on the independent group of cancer vs. control group. However, some studies included multiple control groups
(e.g., disease and normal control). Thus, the total No. of studies per subgroup of control group is higher than the total number of the included studies in
our meta-analysis.
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http://www.biomedcentral.com/1471-2407/13/393anxiety in cancer patients compared with disease control
group (Depression: OR = 6.03, 95% CI = 4.23-8.61, I2 =
65.5%; Anxiety: OR= 4.40, 95% CI = 3.05-6.36, I2 = 61.6%)
were lower than in those compared with normal control
group (Depression: OR= 13.58, 95% CI = 6.26-29.46, I2 =
79.7%; Anxiety: OR= 15.47, 95% CI = 10.00-23.95, I2 = 0%).
ORs were also obtained for studies using different
methods of depression and anxiety assessment. Although
no difference of depression was observed in studies utilizing
clinical diagnosis compared with self-report, a significant
smaller OR of anxiety was observed in studies utilizing
self-reports (OR = 5.83, 95% CI = 3.64-9.34, I2 = 75.4%)
compared with clinical diagnosis (OR = 8.42, 95% CI =
4.83-14.70, I2 = 36.6%).
Due to the small number of studies, the subgroup
comparison of depression and anxiety in different types
of cancer patients were not analyzed.
Publication bias
Visual inspection of the funnel plot indicated some
publication bias, and the Begg’s test and Egger’s test
further suggested publication bias in depression (Begg’s test,P = 0.021; Egger’s test, P = 0.019) and anxiety (Begg’s test,
P = 0.15; Egger’s test, P = 0.017) in our meta-analysis.
Discussion
At the beginning of discussion, we would assess the het-
erogeneity and study quality in the present meta-analysis.
First, we performed strict inclusion criteria, random effects
models and subgroup analyses to control and reduce the
heterogeneity. However, the heterogeneity was still rela-
tively higher, and the conclusion should be considered
with some caution. Second, the Newcastle-Ottawa Scale
was used to assess the study quality. We only identified
two high-quality studies. The bias of medium-quality and
low-quality studies mainly included selection of cases and
assessment of outcome or exposure. Quality assessment
indicated some methodological weaknesses, which could
weaken the internal validity.
The overall prevalence of depression and anxiety in
Chinese patients with cancer were 54.9% (range: 20%-89%)
and 49.69% (range: 20%-89.13%) in our meta-analysis,
suggesting that depression and anxiety also did coexist in
Chinese cancer patients, similar to this situation in foreign
NOTE: Weights are from random effects analysis
Overall  (I-squared = 72.2%, p = 0.000)
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Tao et al. (2005)
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Figure 4 Forest plot for the meta-analysis of anxiety in adults with and without cancer. Note: Some studies included multiple cancer types
(e.g., liver and breast cancer) and control groups (e.g., disease and normal control) in our meta-analysis. Thus, the total number of independent
group in the forest plot is higher than the total number of the included studies in our meta-analysis.
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Figure 3 Forest plot for the meta-analysis of depression in adults with and without cancer. Note: Some studies included multiple cancer
types (e.g., liver and breast cancer) and control groups (e.g., disease and normal control) in our meta-analysis. Thus, the total number of
independent group in the forest plot is higher than the total number of the included studies in our meta-analysis.
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Table 4 Odds ratios of depression and anxiety in adults with and without cancer: subgroup analyses
Subgroups No. of studies No. of subjects OR 95% CI Q I2 (%) P§
Depression
Control group 0.013
Disease control 13 2554 6.03 4.23-8.61 37.63*** 65.5
Normal control 8 1286 13.58 6.26-29.46 34.56*** 79.7
Method of depression assessment 0.094
Clinical diagnosis 5 1010 12.41 5.16-29.84 23.33*** 78.6
Self-report questionnaire 12 2474 6.83 4.70-9.93 52.23*** 71.3
Cancer type -
Breast cancer 3 380 10.84 1.44-81.85 14.83*** 86.5
Liver cancer 3 794 4.54 2.92-7.05 5.20 42.3
Lung cancer 2 400 4.20 2.57-6.88 0.34 0
Anxiety
Control group 0.000
Disease control 11 2154 4.40 3.05-6.36 28.62** 61.6
Normal control 6 786 15.47 10.00-23.95 2.44 0
Method of anxiety assessment 0.013
Clinical diagnosis 4 650 8.42 4.83-14.70 6.31 36.6
Self-report questionnaire 10 1974 5.83 3.64-9.34 48.78*** 75.4
Cancer type -
Breast cancer 3 390 8.24 3.49-19.44 4.22 52.6
Liver cancer 2 394 2.95 1.87-4.63 0.87 0
**p < 0.01.
***p < 0.001.
§ P of comparison between these subgroups.
Note: The No. of studies per row is based on the independent group of cancer vs. control group. However, some studies included multiple control groups
(e.g., disease and normal control). Thus, the total No. of studies per subgroup of control group is higher than the total number of the included studies in our
meta-analysis. -, no report.
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http://www.biomedcentral.com/1471-2407/13/393countries [17,21]. This situation should be noticed because
comorbid anxiety and depressive disorders tend to
have severe symptoms, poorer outcomes and greater
use of healthcare resources than those with a single dis-
order [67]. Meanwhile, the results were slightly higher
than some empirical studies assessing the prevalence of
depression and anxiety in China [12-14].
We also compared our results with other four relatively
comprehensive reviews of depression/anxiety in cancer
patients: (1) the review of Pirl reported the prevalence
of depression (10%-25%) based on 350 English-language
literatures published between 1966 and 2001 [68]; (2)
Hotopf showed the prevalence of depression for self-
reporting questionnaire (29%) and clinical diagnosis (15%)
based on 46 literatures published before 2000 [9]; (3) Van’t
Spijker indicated the prevalence of depression (0%-46%)
and anxiety (0.9%-49%) from 58 studies published from
1980 to 1994 [10]; (4) Mitchell reported the prevalence of
depression (20.7%-24.6%) and anxiety (9.8%-10.3%) of 94
interview-based studies published before 2010 [7]. There
might be several reasons for the different prevalence. First
explanation might be that we only identified 17 eligiblestudies, but other reviews included at least 46 studies. Our
results may be overestimated due to the little studies and
high data fluctuation. Second explanation might be that
most of the included studies of these reviews are from de-
veloped countries which have lower prevalence of mental
health problems as compared to developing countries like
China [69]. Third explanation might be that depression and
anxiety in cancer patients were assessed using different
questionnaires. The included studies of these reviews
mainly used the Hospital Anxiety and Depression Scale
(HADS), but SDS/SAS was the most commonly used in
our meta-analysis. Last explanation might be that many
studies of these reviews used clinical diagnosis like HRSD/
HRSA, but only five studies of our meta-analysis employed
clinical diagnosis method. Some studies indicated that the
prevalence of depression and anxiety would be overestimate
by self-report questionnaires compared with standardized
clinical diagnoses [20,70].
Only reporting the prevalence of depression and anxiety
in Chinese cancer patients is not enough, it is important
that comparable control groups are involved so that the
level of depression and anxiety in cancer patients can be
Yang et al. BMC Cancer 2013, 13:393 Page 13 of 15
http://www.biomedcentral.com/1471-2407/13/393reliably and accurately determined. The level of depression
(OR = 7.85, 95% CI = 5.56-11.07) and anxiety (OR = 6.46,
95% CI = 4.36-9.55) were significantly higher in adults with
cancer compared with those without. This is the first meta-
analysis reporting depression and anxiety in Chinese cancer
patients compared with those without. A meta-analytical
review also reported depression and anxiety in cancer pa-
tients compared with non-cancer group [10], but it yielded
an overall effect size of d-value (mean difference), rather
than OR/RR.
Through the subgroups analysis of control groups
(disease control vs. normal control), cancer patients
compared with normal group experienced the higher
level of depression/anxiety than them compared with
disease group at the 0.05 significance level. More im-
portantly, cancer patients were significantly more de-
pressed and anxious when compared with normal and
disease groups, respectively. The majority of studies
mainly focused on the psychological disorders in can-
cer patients and ignored the role and type of control
group [7-9,12-14,68]. The results showed that the odds
of depression/anxiety were nearly 4–6 times as high in
cancer patients, even when compared with disease control
including patients with chronic hepatitis [56,58], diabetes
[63], tuberculosis [51], benign tumor [62], and other non-
cancer medical patients [50,52,54,55,57,60,61,65]. However,
the different level of depression/anxiety between cancer
patients and non-cancer populations has been controver-
sial. The study of Reyes-Gibby indicated that respondents
with a history of cancer had excess risk for depression
(OR = 1.21; 95% CI = 1.06-1.37) compared to those with-
out [71]. But some studies demonstrated that depression
was common not only among cancer patients, but also
nearly equally among non-cancer diseases [72,73].
Some studies suggested the discrepancy between clin-
ical diagnosis and self-reports measuring depression/
anxiety among cancer patients [29,74], and indicated the
results would be overestimate by self-report question-
naires compared with clinical diagnoses [20,70]. Our re-
sults seemed to be consistent with the conclusion above.
The prevalence of depression/anxiety in cancer patients
was higher in self-reports compared with clinical diagno-
sis, and this situation also occurred in non-cancer group.
However, when control groups were involved, we found
that a significant smaller OR of anxiety was observed in
studies utilizing self-reports compared with clinical diagno-
sis, although not significantly difference between clinical
diagnoses and self-reports of depression. This discrepancy
may result from the same reason that these studies only fo-
cused on the cancer patients and ignored the control group
when different assessment methods of depression and anx-
iety were used [20,29,70,71]. However, only five and four
studies with a combined population of 1010 and 650 were
conducted to measure depression/anxiety using clinicaldiagnoses based on HRSD/HRSA, it was necessary to
consider that our results might be influenced by small
number of studies.
Implication
There are several theoretical and practical implications
through our meta-analysis. In theory, future studies
assessing psychological disorders among cancer patients
should include and specify control group. Thus, they
could explore the difference levels of depression/anxiety
between cancer patients and other populations, including
other non-cancer diseases, and on the other hand, a whole
new perspective would be provided for researchers on the
use of self-reports and clinical diagnosis to assess depres-
sion/anxiety in cancer patients when control groups were
involved. In practice, first, some studies have shown that it
is necessary to evaluate the prevalence of depression and
anxiety before any effects can be provided for optimum
care among cancer patients and reduction of psychological
disorders [17,18,29]. The present meta-analysis provided
the necessary preparations for oncologists and physicians
to treat and manage depression and anxiety in Chinese
cancer patients; second, although a brief psychological
intervention could promote the quality of life and reduce
depression and anxiety among cancer patients [75], oncol-
ogists and physicians still remained poor at detecting and
treating their cancer patients’ psychological problems
[76-78]. There might be many reasons for this situation,
but one of these reasons could be that oncologists and
physicians were unaware of the levels of depression and
anxiety in cancer patients. This meta-analysis showed that
cancer patients had higher prevalence of depression and
anxiety, indicating that depression and anxiety in Chinese
cancer patients should be received sufficient attention.
Limitation
The present meta-analysis had several limitations. First,
although some studies demonstrated that depression
and anxiety might play a causal role of cancer [25,79],
the present meta-analysis was based on cross-sectional
studies, which could not determine the causation or
temporality of this association between the development
of cancer and depression/anxiety. Second, a lot of studies
showed that there was a significant relationship between
depression/anxiety in cancer patients and age [18,80], can-
cer type [10,81,82], gender [83,84], income [85] and so on,
but our meta-analysis did not provide enough information
and number of studies regarding these potential moderat-
ing factors. Third, although we employed subgroup analysis
to explore potential sources of heterogeneity including con-
trol group, methods of depression/anxiety assessment and
cancer types, the subgroup analysis could not reduce I2
to 50% or less in many cases. Fourth, only five and four
studies with a combined population of 1010 and 650
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http://www.biomedcentral.com/1471-2407/13/393were conducted using HRSD/HRSA to measure clinically
significant anxiety and depression. Thus, depression and
anxiety in our meta-analysis more often referred to the de-
pressive symptom and anxiety symptom. Fifth, we did not
find any international literatures that meet our inclusion
and exclusion criteria. It might be because that the inter-
national journals require the papers at a high level com-
pared with Chinese journals, and international journals
maybe not receive the simple descriptive research. Sixth, as
some studies included multiple groups in the meta-analysis,
cancer patients or people in control group were included
twice when calculating the overall OR of depression/
anxiety. This will overestimate the precision. Finally, the
high risk of publication bias is another (and perhaps the
most important) limitation.
Conclusions
We conclude that Chinese adults with cancer had higher
prevalence rates of depression and anxiety compared with
control group, and the same situation is observed in sub-
group analyses. The findings support that the prevalence of
depression and anxiety among adults with cancer should
receive more attention in Chinese medical settings.
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